Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study

(2013) M. Puig-Vives et al.   GYNECOLOGIC ONCOLOGY

Mortality and recurrence patterns of breast cancer patients diagnosed under a screening programme versus comparable non-screened breast cancer patients from the same population: analytical survey from 2002 to 2012

(2013) A. García Fernández et al.   TUMOR BIOLOGY

Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: analytical survey from 1997 to 2012

(2013) Antonio García Fernández et al.   TUMOR BIOLOGY

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

(2012) W. Eiermann et al.   ANNALS OF ONCOLOGY

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer

(2012) Malek B Hannouf et al.   BMC CANCER

Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer

(2012) Shelby D. Reed et al.   GENETICS IN MEDICINE

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX

(2011) S. Aebi et al.   ANNALS OF ONCOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design

(2011) W. Eiermann et al.   BREAST

High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?

(2011) A. C. Regierer et al.   BREAST CANCER RESEARCH AND TREATMENT

Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer

(2011) L. C. Collins et al.   BREAST CANCER RESEARCH AND TREATMENT

Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor-Positive Breast Cancer

(2011) A. I. Phipps et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: A retrospective clinical study

(2011) P. Sanpaolo et al.   EJSO

Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast Cancer

(2011) Peter S. Hall et al.   JNCI-Journal of the National Cancer Institute

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization

(2010) Shmuel H. Klang et al.   VALUE IN HEALTH

Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004

(2009) Carol A. Parise et al.   Breast Journal

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

(2009) Ana M. Gonzalez-Angulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene-Expression Signatures in Breast Cancer

(2009) Christos Sotiriou et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

(2008) James J. Dignam et al.   BREAST CANCER RESEARCH AND TREATMENT

The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004

(2008) Monica Brown et al.   CANCER

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy

(2008) Paul L. Nguyen et al.   JOURNAL OF CLINICAL ONCOLOGY